United States· US:0078-0883_659b0142-cf3f-4af9-ad14-79f8c88978af
ADAKVEO
A medicinal product containing crizanlizumab, registered in United States by Novartis Pharmaceuticals Corporation.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- crizanlizumab
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc11007808836110 mL in 1 VIAL, GLASS (0078-0883-61)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Crizanlizumab in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAdakveo 10 mg/mlNovartis Europharm
- SpainADAKVEO 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONNovartis Europharm Limited
- FinlandAdakveoNovartis Europharm Limited
- FranceADAKVEO 10 mg/mL, solution à diluer pour perfusionNOVARTIS EUROPHARM (IRLANDE)
- United KingdomAdakveo 100mg/10ml concentrate for solution for infusion vialsNovartis Pharmaceuticals UK Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/16ca5ffa-a637-4e1c-b287-80f46a1ae3d1 GET /v1/drugs/16ca5ffa-a637-4e1c-b287-80f46a1ae3d1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"productid": "0078-0883_659b0142-cf3f-4af9-ad14-79f8c88978af",
"productndc": "0078-0883",
"dosage_form": "INJECTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "CRIZANLIZUMAB",
"proprietary_name": "ADAKVEO",
"active_ingred_unit": "mg/mL",
"application_number": "BLA761128",
"marketing_category": "BLA",
"nonproprietary_name": "crizanlizumab",
"start_marketing_date": "20191115",
"active_numerator_strength": "10"
}See everything about crizanlizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.